DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie…

#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY

Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain) Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited #ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR

Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs Contrasting w/ data from real world TNF Interesting data but small sample size & events N https://t.co/gv8uvcThMD Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg

• Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Anky…

Interesting Abs 0825: MAS was most often caused 2nd to a benign disease. Most common presentation: fever w/ cytopenias. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 ass'd w/ higher mortality. #ACR22 @RheumNow https://t.co/HEuMedE9Rh https://t.co/6f4bf7x9Hh

• Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective St…

Initial Remibrutinib (oral, covalent, and highly specific inhibitor of Bruton’s tyrosine kinase (BTK)) data in SS shows good efficacy and safety. Plenary Abs 1113 #ACR22 @RheumNow https://t.co/5Zr0Y1ueAv https://t.co/Iy194YUWNC

• Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…

RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd

We're used to originator-to-biosimilar switches. Widespread biosim use means we now see biosim-biosim switches (incl as second switch) DANBIO data retention good I see the hallmarks of nocebo still an issue I think we can all agree: ongoing education important #ACR22 @RheumNow https://t.co/6PcMfEEozk

Yes. But this only accounts for 1/3 of risk to develop clinical RA. We need a better understanding of the other 2/3 so we can propose efficient preventive interventions. #ACR22 @RheumNow https://t.co/RRzlAISFK3

• https://twitter.com/doctorRBC/status/1591825586401710080

@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis. Certain HLA haplotypes more linked with autoimmune diseases are present. #ACR @RheumNow

@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX

• Association Between Stringent Clinical Measures of Disease Activity and Clinica…

Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7

• Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA - ACR Meeting …

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M